Magnesium sulfate as an adjuvant therapy in neonatal hypoxia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20180720002

Enrollment

Unknown

Registered

2018-07-20

Start date

2018-07-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neonatal hypoxia hypoxic ischemic encephalopathy S100&#45

Interventions

using magnesium sulfate (MgSo4) in neonatal HIE. ,using melatonin in neonatal HIE

Experimental Drug,Experimental Drug

prospective open labelled clinical trial by using mgso4 on hypoxic neonates ,prospective open labelled clinical trial by using melatonin on hypoxic neonates

Eligibility

Sex/Gender

All

Age

0 Days to 0 Days

Inclusion criteria

Inclusion criteria: hypoxic ischemic encephalopathy, S100-b, magnesium sulfate, neonates

Exclusion criteria

Exclusion criteria: congenital anomalies, intra uterine growth retardation (I.U.G.R), neonatal sepsis, infant of diabetic mother (I.D.M).

Design outcomes

Primary

Measure	Time frame
hypoxia 14 days after end of the study pulse oximetry	—

Secondary

Measure	Time frame
neonatal survival and grades of hypoxic ischemic encephalopathy 3 days our neonatal unit statistics and Sarnat staging of hypoxia	—

Countries

Egypt

Contacts

Public Contactneama soliman

Tanta University

neamaali@hotmail.com01227940773

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026